Peak to strive to achieve "five breakthroughs"
Release time:
2020-08-14
Jiang Xiaomeng asked
peak to strive to achieve "five breakthroughs" at the work analysis meeting in the first half of the year
report 7# October 19 afternoon, in the concluding speech of the group company's work analysis meeting in the first half of the year, chairman Jiang Xiaomeng asked all enterprises to strive to achieve breakthroughs in five aspects.
Jiang Xiaomeng said in his speech that if an enterprise wants to develop, it must not be complacant, but must continue to innovate and break through itself. Although the peak has achieved good business performance in recent years, in order to achieve the grand goal of "creating a century-old peak", we must constantly challenge ourselves, innovate and enhance our strength in order to achieve greater development. In his speech, Jiang Xiaomeng put forward the requirements of "breakthrough" from five aspects: to achieve a breakthrough in development, all enterprises should really recognize themselves and the external environment, clarify their own positioning and development direction, and formulate practical and feasible development strategies according to the changes of the situation. To achieve a breakthrough in technology, the pharmaceutical sector should strengthen the research and development of new drugs and make products with real exclusive and technical content; the cement sector should strengthen all kinds of technological transformation according to the production needs, so as to establish the technical and cost advantages in the regional market. To achieve a breakthrough in marketing, we must boldly use new people, adopt new models and new mechanisms to expand the market, further achieve market segmentation, and improve market coverage. Achieve breakthroughs in management, widely advocate the "amoeba" management concept, increase the introduction of talents, seriously reflect on the shortcomings of the employment system, and achieve the overall improvement of the quality of the staff and the improvement of labor productivity. To make a breakthrough in the system, both the group level and the subordinate enterprises should keep pace with the times and constantly promote the system innovation according to the needs of industrial upgrading and post optimization, so as to make it truly meet the needs of enterprise development.
Jiang Xiaomeng said that the most fundamental breakthrough in management is the breakthrough of people and thinking concepts. Enterprise managers at all levels should recognize the risks and challenges they are facing, their own strengths and weaknesses, continuously improve their learning ability, business ability and innovation ability, adopt new measures and new methods, and practice the company's "internal skills" well, with higher requirements and better performance to present the 23rd anniversary of peak entrepreneurship 60. (Reporter
Fu Yiwu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page